Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/13179
Title: A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders.
Authors: Louis, William J;Krum, Henry;Conway, Elizabeth L
Affiliation: Department of Clinical Pharmacology and Therapeutics, Austin Hospital, Heidelberg, Victoria, Australia.
Issue Date: 1-Aug-1994
Citation: Drug Safety; 11(2): 86-93
Abstract: Carvedilol is a nonselective beta-adrenoceptor blocking vasodilator drug that may be a promising new agent in the management of cardiovascular disease. The rationale for the development of agents of this type is that the alpha-blocking component may overcome the direct vasoconstrictor consequence of beta 2-blockade, whilst the beta-blocker component may inhibit the reflex tachycardia that occurs following alpha-blockade. In clinical trials published to date, carvedilol has been demonstrated to be effective as an antihypertensive agent as monotherapy and also as additional therapy in those patients whose blood pressure cannot be controlled on other standard agents. It is also effective in the management of angina. Carvedilol has beneficial haemodynamic effects in patients with congestive heart failure. beta-Blocker vasodilator drugs of this type may be particularly useful in this condition as the vasodilator component of the drug may overcome the initial negative inotropy of the beta-blocker. In addition, carvedilol possess potentially useful pharmacological actions. In particular, the drug has antimitogenic and free radical scavenging effects that may make it a useful therapy in the long term management of atherosclerotic vascular disease. Its metabolic profile is also favourable, presumably on the basis of its alpha-blocking properties. Thus, beta 2-mediated adverse effects on peripheral vascular tone, glycaemic control and lipid status appear to be offset by the alpha-blocking property of the drug. Carvedilol thus far appears to be well tolerated, with postural dizziness the major adverse effect, especially in the elderly. As with nonselective beta-blockers, carvedilol is contraindicated in patients with asthma.
Internal ID Number: 7946002
URI: http://ahro.austin.org.au/austinjspui/handle/1/13179
URL: http://www.ncbi.nlm.nih.gov/pubmed/7946002
Type: Journal Article
Subjects: Adrenergic beta-Antagonists.adverse effects.therapeutic use
Carbazoles.adverse effects.therapeutic use
Cardiovascular Diseases.drug therapy
Humans
Propanolamines.adverse effects.therapeutic use
Risk Assessment
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.